HeartFlow and Longview End SPAC Merger

HeartFlow and Longview Acquisition Corporation have mutually terminated a planned merger. The Redwood City, CA-based company first announced the Special Purpose Acquisition Corporation merger July of 2021.  

The firm said in a release the merger was terminated because of unfavorable market conditions.

HeartFlow was launched 11 years ago. The company’s core product, the HeartFlow FFRCT Analysis, is a non-invasive cardiac test for stable symptomatic patients with coronary artery disease (CAD).

With the HeartFlow FFRCT Analysis, the company currently targets a $10 billion total addressable market opportunity that it plans to expand to more than $50 billion through the introduction of new products, new customer site additions and increased utilization of HeartFlow in existing healthcare systems over the coming years.

Not all SPACs go off without a hitch. Back in August of 2021, declining COVID-19 testing volume led LumiraDx to reduce the terms of its valuation from $5 billion to $3 billion. The London-based company said in April of 2021 that it would merge with CA Healthcare Acquisition Corp. The deal finally closed in September.